MEC Plus – MyMedflix Member Portal

Skip to content

Live Events

Live Events

Live Events

Live Events

MEC Plus

Events

Type of Media

Title

Speciality

Author / Speaker

Search Entries:

«
1
…
22
23
24
25
26
…
100
»

Breast Cancer Update in Hormone Sensitive Breast Cancer

Breast Cancer Update in Hormone Sensitive Breast Cancer

Lauren Carcas, MD

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

Joyce O’Shaughnessy, MD

New Developments in EGFR and K-RAS Therapies in NSCLC

New Developments in EGFR and K-RAS Therapies in NSCLC

Edgardo S. Santos, MD, FACP

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Jessica Lin, MD

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Luis E. Raez, MD, FACP, FCCP

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

Jason Porter, MD

New Developments in CLL

New Developments in CLL

Javier Pinilla-Ibarz, MD, PhD

Most Relevant News in Multiple Myeloma in 2023

Most Relevant News in Multiple Myeloma in 2023

Sergio Giralt, MD, FACP, FASTCT

Modern Challenges and New Options for B-cell NHL

Modern Challenges and New Options for B-cell NHL

Eduardo Sotomayor, MD

Update on T-Cell Lymphomas

Update on T-Cell Lymphomas

Juan Carlos Ramos, MD

What’s After PACIFIC? Can We Raise the Bar?

What’s After PACIFIC? Can We Raise the Bar?

Jhanelle Gray, MD

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

Ticiana Leal, MD

Updates in Bispecific Antibodies in NSCLC

Updates in Bispecific Antibodies in NSCLC

Lyudmila Bazhenova, MD

TROP-2 and AXL as Targets in NSCLC

TROP-2 and AXL as Targets in NSCLC

Stephen Liu, MD

The Role of Co-Mutations with Immunotherapy Response in NSCLC

The Role of Co-Mutations with Immunotherapy Response in NSCLC

Ferdinando Skoulidis, MD

The New Role of Microbiome in Lung Cancer Immunotherapy

The New Role of Microbiome in Lung Cancer Immunotherapy

David Carbone, MD

The Importance of TIME in Cancer Fight: How to Target It?

The Importance of TIME in Cancer Fight: How to Target It?

Hossein Borghaei, DO

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

Paul Bunn, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

Jorge E. Gomez, MD

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

Christine M. Lovly, MD, PhD

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

Puneeth Iyengar, MD

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Corey Langer, MD

ROS-1 & B-Raf Inhibitors: New Developments

ROS-1 & B-Raf Inhibitors: New Developments

Julia Rotow, MD

Role of SHP2 Inhibitors Alone or in Combination

Role of SHP2 Inhibitors Alone or in Combination

Rachel Sanborn, MD

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Puneeth Iyengar, MD

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Suresh Ramalingam, MD

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

John Heymach, MD

Radiation Induced Immune-Response in NSCLC

Radiation Induced Immune-Response in NSCLC

Jeffrey Bradley, MD

Predictive Biomarkers for SCLC

Predictive Biomarkers for SCLC

Janakiraman Subramanian, MD

PARP Inhibitors in SCLC

PARP Inhibitors in SCLC

Charles Rudin, MD, PhD

Displaying 691 - 720 of 2,995

«
1
…
22
23
24
25
26
…
100
»

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.